Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Price:
64.39
CNY
-3.19%
Market Closed
Market Cap:
¥11.4B
Income Statement
Earnings Waterfall
Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Income Statement
Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co Ltd
Currency: CNY
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
0
|
1
|
1
|
3
|
3
|
4
|
4
|
3
|
4
|
4
|
4
|
4
|
3
|
0
|
|
| Revenue |
1 071
N/A
|
1 100
+3%
|
1 147
+4%
|
1 171
+2%
|
1 179
+1%
|
1 150
-2%
|
1 123
-2%
|
1 117
0%
|
1 154
+3%
|
1 231
+7%
|
1 307
+6%
|
1 350
+3%
|
1 340
-1%
|
1 335
0%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(180)
|
(190)
|
(201)
|
(198)
|
(219)
|
(224)
|
(234)
|
(226)
|
(255)
|
(292)
|
(317)
|
(344)
|
(359)
|
(368)
|
|
| Gross Profit |
891
N/A
|
910
+2%
|
946
+4%
|
972
+3%
|
960
-1%
|
926
-4%
|
888
-4%
|
891
+0%
|
899
+1%
|
939
+4%
|
990
+5%
|
1 006
+2%
|
982
-2%
|
967
-1%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(687)
|
(690)
|
(744)
|
(750)
|
(727)
|
(703)
|
(664)
|
(687)
|
(679)
|
(719)
|
(760)
|
(793)
|
(785)
|
(760)
|
|
| Selling, General & Administrative |
(542)
|
(544)
|
(561)
|
(569)
|
(559)
|
(534)
|
(494)
|
(478)
|
(496)
|
(532)
|
(556)
|
(558)
|
(550)
|
(523)
|
|
| Research & Development |
(204)
|
(206)
|
(218)
|
(217)
|
(236)
|
(238)
|
(234)
|
(219)
|
(243)
|
(241)
|
(258)
|
(242)
|
(271)
|
(284)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(29)
|
0
|
0
|
0
|
(43)
|
0
|
0
|
0
|
(41)
|
0
|
0
|
|
| Other Operating Expenses |
59
|
60
|
35
|
65
|
68
|
69
|
65
|
53
|
59
|
53
|
54
|
48
|
35
|
48
|
|
| Operating Income |
203
N/A
|
221
+8%
|
203
-8%
|
222
+10%
|
233
+5%
|
224
-4%
|
225
+0%
|
205
-9%
|
220
+8%
|
220
0%
|
230
+5%
|
213
-8%
|
196
-8%
|
207
+6%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
51
|
44
|
46
|
38
|
38
|
35
|
36
|
37
|
33
|
37
|
31
|
39
|
38
|
35
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Total Other Income |
3
|
3
|
8
|
1
|
1
|
1
|
1
|
0
|
(0)
|
(0)
|
(0)
|
1
|
1
|
1
|
|
| Pre-Tax Income |
257
N/A
|
267
+4%
|
257
-4%
|
262
+2%
|
273
+4%
|
260
-5%
|
262
+1%
|
242
-8%
|
253
+5%
|
256
+1%
|
262
+2%
|
253
-3%
|
235
-7%
|
243
+3%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(14)
|
(17)
|
(15)
|
(15)
|
(19)
|
(17)
|
(17)
|
(15)
|
(13)
|
(15)
|
(12)
|
(14)
|
(11)
|
(15)
|
|
| Income from Continuing Operations |
243
|
250
|
242
|
247
|
254
|
243
|
245
|
227
|
241
|
242
|
250
|
238
|
224
|
228
|
|
| Net Income (Common) |
243
N/A
|
250
+3%
|
242
-3%
|
247
+2%
|
254
+3%
|
243
-4%
|
245
+1%
|
227
-7%
|
241
+6%
|
242
+0%
|
250
+3%
|
238
-5%
|
224
-6%
|
228
+2%
|
|
| EPS (Diluted) |
2.02
N/A
|
2.08
+3%
|
2.01
-3%
|
1.4
-30%
|
2.11
+51%
|
2.03
-4%
|
2.04
+0%
|
1.29
-37%
|
1.37
+6%
|
1.35
-1%
|
1.45
+7%
|
1.36
-6%
|
1.27
-7%
|
1.3
+2%
|
|
Switch to:
Switch to:
See Also
Discover More
